CClinicalTrials.gg
Sign In
CompletedNCT06564727Updated Aug 21, 2024

Uniportal VATS Resection for Pulmonary Aspergilloma : Evaluation of Prognostic Factors in a Single Center Experience

An interventional study of Uniportal VATS approach and VATS approach in Pulmonary Aspergillosis, Surgery-Complications and Thoracic Diseases, sponsored by Hassan II University. Completed at 1 site in Morocco. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Hassan II University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 7 months after the study started (first participant enrolled Jan 2017, registered Aug 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Sex
All
01

Study summary

The objective of this study was to report our experience with U-VATS resection and to evaluate our surgical outcomes with an analysis of postoperative complications. The investigators also estimate the prognostic factors that influence the morbidity and the conversion.

Read the detailed description

Evaluation of prognostic factors Tuberculosis Hemoptysis Type of aspergilloma presence of complete adherence Procedure

02

Conditions studied

  • Pulmonary Aspergillosis
  • Surgery-Complications
  • Thoracic Diseases
03

In context

Aspergillosis

201 studies on the registry are indexed under Aspergillosis; 22 are open to participants now.

This study's enrollment of 51 is close to the median of 50 across 106 interventional studies indexed under Aspergillosis.

Browse Aspergillosis studies →

Lead sponsor

Hassan II University is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Treatment using uniportal VATS

Exclusion criteria

Exclusion Criteria:

  • Resection using thoracotomy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Uniportal VATS approach

    patient treated by Uniportal VATS technique

    Procedure: Uniportal VATS approach

  • Active comparator
    VATS resection

    patients treated by VATS technique

    Procedure: VATS approach

Interventions

  • ProcedureUniportal VATS approach

    Uniportal VATS resection for simple pulmonary aspergilloma

  • ProcedureVATS approach

    VATS resection for complex pulmonary aspergilloma

06

What researchers measure

Primary outcomes

  1. postoperative complications

    evaluate the complication at 30 days

    Time frame: 30 days

07

Study locations

1 site
  • Hassan II University
    Casablanca, 20000, Morocco
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06564727
Lead sponsor
Hassan II University
Responsible party
Sara WAGUAF (principal investigator, Hassan II University) — Principal investigator
First posted
Aug 21, 2024
Start date
Jan 1, 2017
Primary completion
Jan 1, 2020
Completion
Jan 30, 2020
Last update
Aug 21, 2024

Study contacts

sara WAGUAF
principal investigator · Hassan II University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Aspergillosis→

Other studies from this sponsor

Hassan II University

Start the discussion